Literature DB >> 1756691

New carnitine derivatives for the therapy of cutaneous ulcers in vasculopathics.

P Pola1, R Flore, M Serricchio, P Tondi.   

Abstract

The treatment of arterial and venous cutaneous ulcers in vasculopathic patients is a difficult task, since it requires the prolonged administration of drugs which are often unable to correct the various pathogenetic factors, including rheological disorders, responsible for the lesions. The authors, basing themselves upon recent studies demonstrating the rheological and vasoactive as well as metabolic activities of propionyl l-carnitine, have decided to examine this substance for the treatment of arterial and venous cutaneous ulcers of the lower extremities. Propionyl l-carnitine administered orally or intravenously to eighteen vasculopathics with cutaneous ulcers was responsible for the complete or nearly complete regression of trophic lesions in 78.9% of the patients. Therapeutic failure or only modest results were observed in four patients. In addition a highly significant increase in flow velocity was observed in arteriopathic patients. It is particularly important to note that these clinical results were obtained in patients refractory to all other forms of therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1756691

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  5 in total

Review 1.  Adipocytes in skin health and disease.

Authors:  Guillermo Rivera-Gonzalez; Brett Shook; Valerie Horsley
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

Review 2.  Propionyl-L-carnitine.

Authors:  L R Wiseman; R N Brogden
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

Review 3.  Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.

Authors:  Carmen Mingorance; Rosalía Rodríguez-Rodríguez; María Luisa Justo; María Alvarez de Sotomayor; María Dolores Herrera
Journal:  Vasc Health Risk Manag       Date:  2011-03-28

4.  Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases.

Authors:  Giuseppe Merra; Giovanni Gasbarrini; Lucrezia Laterza; Marco Pizzoferrato; Andrea Poscia; Franco Scaldaferri; Vincenzo Arena; Francesca Fiore; Achille Cittadini; Alessandro Sgambato; Francesco Franceschi; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

5.  Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction.

Authors:  Maria Giovanna Scioli; Pietro Lo Giudice; Alessandra Bielli; Valeria Tarallo; Alfonso De Rosa; Sandro De Falco; Augusto Orlandi
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.